NEW YORK (Reuters) - Ligand Pharmaceuticals Inc. on Monday said Eli Lilly and Co. will advance its experimental type 2 diabetes drug into late stage clinical trials.
The experimental product, known as LY519818, is an oral, once-daily pill that affects a protein called peroxisome proliferator-activated receptor (PPAR). It was discovered through a research collaboration between Lilly and Ligand.
PPARs play a key role in enhancing cellular responses to insulin, and in fat tissue stores and metabolism. The companies expect efficacy and safety data from a recently completed phase II study to be presented at a major scientific meeting this year.
Ligand said it receives research funding from Lilly along with milestone payments as products move through the development process and royalties on sales. Specific terms of the collaboration were not immediately available.
MeSH Headings:Clinical Trials: Environment and Public Health: Epidemiologic Methods: Evaluation Studies: Health: Health Occupations: Health Services Administration: Medicine: Investigative Techniques: Population Characteristics: Preventive Medicine: Public Health: Quality of Health Care: Specialties, Medical: Drugs, Investigational: Epidemiologic Study Characteristics: Clinical Trials, Phase II: Health Care Quality, Access, and Evaluation: Health Care Evaluation Mechanisms: Analytical, Diagnostic and Therapeutic Techniques and Equipment: Biological Sciences: Health CareCopyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
